Silencing PARP1 at the Gene Level: A G-Quadruplex-Binding Small Molecule Sidesteps PARP Inhibitor Toxicity
- Rather than inhibiting or trapping the PARP1 enzyme like approved PARP inhibitors (PARPis), researchers targeted the PARP1 gene promoter itself to shut down PARP1 production at the transcriptional level, aiming to avoid the hematologic toxicity and resistance mechanisms associated with PARPi-mediated PARP1 trapping.
- The promoter region forms a non-canonical (3+1) hybrid G-quadruplex structure distinguished by an adenine bulge, a distinctive DNA fold not previously exploited as a drug target.
- Combining computational modeling with biophysical characterization, the team identified a small molecule that selectively engages this unusual G-quadruplex architecture.
- In multiple myeloma cells, the compound reduced PARP1 expression, disrupted downstream DNA repair signaling, and triggered DNA damage-associated apoptosis.
- Healthy blood cells were largely spared, pointing to a possible therapeutic window distinct from conventional PARP inhibitor toxicity profiles.
The part that gets me: attacking PARP1 at the promoter instead of the active site. Every PARPi on the market — olaparib, niraparib, talazoparib — works by trapping or inhibiting the protein; the hematologic toxicity and trapping-driven resistance are baked into that mechanism. Silencing transcription via a G-quadruplex sidesteps the whole liability profile, at least on paper. That said, G4-targeting ligands are a rough class to work in — selectivity across the thousands of quadruplex-forming sequences in the genome is the perennial failure mode, not potency. And this (3+1) hybrid fold with an adenine bulge is a genuinely novel pocket, which cuts both ways: interesting SAR territory, but no playbook to lean on. Still early — a validated hit in MM cells, not a lead, let alone a candidate. Worth watching, not betting on yet.